← SynDRA
OLMESARTAN
SynDRA canonical compound SYN0008395 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Primary target(s) | AGTR1 |
|---|
| Mechanism of action | angiotensin receptor antagonist |
|---|
| Indication | hypertension |
|---|
| Disease area | cardiology |
|---|
All known targets
Mechanisms of action (all sources)
- angiotensin receptor antagonist
Cross-references
Synonyms
- NSC-759810
- RNH-6270
- Olmesartan medoxomil impurity, olmesartan-
- RNH 6270
- 8W1IQP3U10
- olmesartan medoxomil impurity a (ep impurity)
- olmesartan medoxomil impurity, olmesartan-(usp impurity)
- NSC 759810
- omesartan
- CHEBI:48416
- olmesartanum
- olmesartanum medoxomilum
- RefChem:55770
- DTXCID0020571
- Olmesartan Acid
- CS-088
- MFCD00914967
- C24H26N6O3
- Votum
- Olmesartan [USAN]
- SMR000466337
- UNII-8W1IQP3U10
- Olmesa
- Olmesartan [USAN:INN:BAN]
- Benicar;Olmetec
- HSDB 8214
- OLM
- Olmesartan medoximil
- OLMESARTAN [MI]
- OLMESARTAN [INN]
- Olmesartan (USAN/INN)
- OLMESARTAN [VANDF]
- EC 646-413-5
- OLMESARTAN [WHO-DD]
- SCHEMBL94037
- MLS000759446
- MLS001424016
- MLS006011945
Reported adverse events
- Hypotension
- Vomiting
- Angioedema
- Rhabdomyolysis
- Asthenia
- Alopecia
- Dizziness
- Nausea
- Hypersensitivity
- Hypertension
- Myopia
- Syncope
Look up OLMESARTAN in the interactive SynDRA portal →